These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37039618)

  • 1. Futibatinib (Lytgobi) for cholangiocarcinoma.
    Med Lett Drugs Ther; 2023 Apr; 65(1674):e69-e70. PubMed ID: 37039618
    [No Abstract]   [Full Text] [Related]  

  • 2. Futibatinib (Lytgobi) for cholangiocarcinoma.
    Roskoski R
    Trends Pharmacol Sci; 2023 Mar; 44(3):190-191. PubMed ID: 36702680
    [No Abstract]   [Full Text] [Related]  

  • 3. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 4. Futibatinib: First Approval.
    Syed YY
    Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
    Lamarca A; Vogel A
    ESMO Open; 2023 Dec; 8(6):102049. PubMed ID: 37922686
    [No Abstract]   [Full Text] [Related]  

  • 6. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 7. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
    Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
    Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrahepatic cholangiocarcinoma: a worthy challenge.
    Bartlett DL
    Cancer J; 2009; 15(3):255-6. PubMed ID: 19556913
    [No Abstract]   [Full Text] [Related]  

  • 9. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK
    Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary neoplasm of the bile duct: A rare precursor of cholangiocarcinoma.
    Verset L; Lucidi V; Demetter P
    Liver Int; 2019 Apr; 39(4):777-778. PubMed ID: 30549408
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholangiocarcinoma in the distal bile duct: a probable etiologic association with choledocholithiasis.
    Nishimura M; Naka S; Hanazawa K; Tani T; Fukami M; Okada S; Fujiyama Y
    Dig Dis Sci; 2005 Nov; 50(11):2153-8. PubMed ID: 16240231
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma development: the resurgence of bile acids.
    Maroni L; Alpini G; Marzioni M
    Hepatology; 2014 Sep; 60(3):795-7. PubMed ID: 24828905
    [No Abstract]   [Full Text] [Related]  

  • 15. Mass-forming intrahepatic cholangiocarcinoma presenting tumor growth in extrahepatic bile duct and superficial spreading.
    Regimbeau JM; Panis Y; Nemeth J; Pocard M; de Claviere G; Soyer P; Valleur P
    Hepatogastroenterology; 2003; 50(49):21-3. PubMed ID: 12629982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
    Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholangiocarcinoma: preventing invasion as anti-cancer strategy.
    Gores GJ
    J Hepatol; 2003 May; 38(5):671-3. PubMed ID: 12713880
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver.
    Petrelli NJ
    Surg Oncol Clin N Am; 2015 Jan; 24(1):xi-xii. PubMed ID: 25444477
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver.
    Wagman LD
    Surg Oncol Clin N Am; 2015 Jan; 24(1):xiii-xiv. PubMed ID: 25444478
    [No Abstract]   [Full Text] [Related]  

  • 20. [A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
    Ogura N; Hoshino M; Hayashi T; Odaira M; Harada H; Hirose S; Funakoshi S
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1665-1667. PubMed ID: 36733169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.